$LRMR
Larimar Therapeutics, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020040314 Filed on August 14, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q4 2019 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.490M $5.320M $3.620M
YoY Change -31.22% 64.71% 8.06%
% of Gross Profit
Research & Development $8.907M $420.0K $3.128M
YoY Change 184.75% -96.34% -74.38%
% of Gross Profit
Depreciation & Amortization -$20.00K $70.00K $60.00K
YoY Change -133.33% 40.0% 20.0%
% of Gross Profit
Operating Expenses $11.40M $7.281M $3.704M
YoY Change 207.75% -50.44% -76.2%
Operating Profit -$11.40M -$3.704M
YoY Change 207.75% -76.2%
Interest Expense $30.00K $60.00K
YoY Change -75.0% -87.12%
% of Operating Profit
Other Income/Expense, Net $69.00K $61.00K
YoY Change 13.11% -128.37%
Pretax Income -$11.33M -$7.250M -$12.13M
YoY Change -6.6% -50.24% -23.13%
Income Tax
% Of Pretax Income
Net Earnings -$11.33M -$7.251M -$3.704M
YoY Change 205.89% -50.23% -76.52%
Net Earnings / Revenue
Basic Earnings Per Share -$1.21
Diluted Earnings Per Share -$1.21 -$2.331M -$3.900M
COMMON SHARES
Basic Shares Outstanding 9.381M
Diluted Shares Outstanding 9.381M

Balance Sheet

Concept 2020 Q2 2019 Q4 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $113.7M $44.06M $91.66M
YoY Change 24.03% -62.68% 20.84%
Cash & Equivalents $112.7M $1.009M $37.24M
Short-Term Investments $1.011M $43.05M $54.42M
Other Short-Term Assets $5.400M $1.000M $800.0K
YoY Change 575.0% -41.18% -38.46%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $119.1M $4.750M $94.00M
YoY Change 26.71% -96.09% 20.46%
LONG-TERM ASSETS
Property, Plant & Equipment $675.0K $274.0K $968.0K
YoY Change -30.27% -26.93% 105.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $80.00K $90.00K $20.00K
YoY Change 300.0% 57.89% -94.4%
Total Long-Term Assets $6.346M $451.0K $9.883M
YoY Change -35.79% 4.4% 459.31%
TOTAL ASSETS
Total Short-Term Assets $119.1M $4.750M $94.00M
Total Long-Term Assets $6.346M $451.0K $9.883M
Total Assets $125.5M $5.201M $103.9M
YoY Change 20.77% -95.73% 30.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.258M $3.539M $2.056M
YoY Change 9.82% -1.42% -31.69%
Accrued Expenses $3.796M $2.259M $3.516M
YoY Change 7.96% -46.98% -20.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.300M $7.300M
YoY Change 32.73% 305.56%
Total Short-Term Liabilities $6.645M $5.895M $13.46M
YoY Change -50.64% -55.7% 45.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $8.500M $11.90M
YoY Change -100.0% -44.08% -35.68%
Other Long-Term Liabilities $6.300M $6.500M $6.400M
YoY Change -1.56%
Total Long-Term Liabilities $6.300M $15.00M $18.30M
YoY Change -65.57% -1.32% -1.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.645M $5.895M $13.46M
Total Long-Term Liabilities $6.300M $15.00M $18.30M
Total Liabilities $12.91M $5.895M $31.70M
YoY Change -59.26% -79.31% 14.12%
SHAREHOLDERS EQUITY
Retained Earnings -$41.14M -$23.13M
YoY Change -93.41%
Common Stock $153.7M $22.44M
YoY Change -94.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $112.5M -$694.0K $543.0K
YoY Change
Total Liabilities & Shareholders Equity $125.5M $5.201M $103.9M
YoY Change 20.77% -95.73% 30.18%

Cashflow Statement

Concept 2020 Q2 2019 Q4 2019 Q2
OPERATING ACTIVITIES
Net Income -$11.33M -$7.251M -$3.704M
YoY Change 205.89% -50.23% -76.52%
Depreciation, Depletion And Amortization -$20.00K $70.00K $60.00K
YoY Change -133.33% 40.0% 20.0%
Cash From Operating Activities -$16.50M -$9.800M -$10.78M
YoY Change 53.06% -17.23% -19.01%
INVESTING ACTIVITIES
Capital Expenditures -$60.00K -$280.0K -$410.0K
YoY Change -85.37% 2700.0% 1950.0%
Acquisitions
YoY Change
Other Investing Activities $22.51M -$4.270M $13.82M
YoY Change 62.88% -129.9% 65.31%
Cash From Investing Activities $22.45M -$4.560M $13.41M
YoY Change 67.41% -131.98% 60.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 95.29M -1.760M -1.820M
YoY Change -5335.71% -200.0% 9000.0%
NET CHANGE
Cash From Operating Activities -16.50M -9.800M -10.78M
Cash From Investing Activities 22.45M -4.560M 13.41M
Cash From Financing Activities 95.29M -1.760M -1.820M
Net Change In Cash 101.2M -16.12M 810.0K
YoY Change 12398.77% -485.65% -116.23%
FREE CASH FLOW
Cash From Operating Activities -$16.50M -$9.800M -$10.78M
Capital Expenditures -$60.00K -$280.0K -$410.0K
Free Cash Flow -$16.44M -$9.520M -$10.37M
YoY Change 58.53% -19.53% -21.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
LARIMAR THERAPEUTICS, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001374690
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Trading Symbol
TradingSymbol
LRMR
dei Entity Small Business
EntitySmallBusiness
true
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
87000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
675000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
97000
dei Local Phone Number
LocalPhoneNumber
511-9056
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 506
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3741000
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19004
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
274000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4252000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1339000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90000
CY2019Q4 us-gaap Assets
Assets
5201000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3539000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2259000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5895000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1009000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
119111000
dei Entity Address City Or Town
EntityAddressCityOrTown
Bala Cynwyd
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei City Area Code
CityAreaCode
844
dei Security12b Title
Security12bTitle
Common Stock
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1011000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 us-gaap Assets Current
AssetsCurrent
4750000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3857670
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
591000
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
112544000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-694000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
125457000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5201000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5427000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
80000
CY2020Q2 us-gaap Assets
Assets
125457000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2258000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3796000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6645000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6268000
CY2020Q2 us-gaap Liabilities
Liabilities
12913000
CY2019Q4 us-gaap Liabilities
Liabilities
5895000
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15356206
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6091250
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15356206
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6091250
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8907000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3128000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13914000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2492000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
576000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4159000
us-gaap Operating Expenses
OperatingExpenses
8428000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8428000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7350000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112673000
dei Entity File Number
EntityFileNumber
001-36510
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15356206
dei Entity Address Address Line1
EntityAddressAddressLine1
Three Bala Plaza East
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1078000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
11399000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11399000
CY2020Q2 lrmr Stock Issued For Merger Value
StockIssuedForMergerValue
37119000
us-gaap Net Income Loss
NetIncomeLoss
-18004000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.33
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18007000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3704000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18073000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
3704000
us-gaap Operating Expenses
OperatingExpenses
18073000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
69000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.21
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6091250
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7736331
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-3000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-3000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11333000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3704000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8428000
CY2020Q1 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
9595000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6674000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
2256000
CY2020Q2 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
8400000
CY2020Q2 lrmr Stock And Pre Funded Warrants Issued During Period Value Private Placement
StockAndPreFundedWarrantsIssuedDuringPeriodValuePrivatePlacement
75350000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
752000
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
15000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
153668000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
22432000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41136000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23132000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-11330000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9381412
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
33000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-3704000
us-gaap Depreciation
Depreciation
55000
CY2019Q1 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
3000000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3000
lrmr Offering Costs Incurred But Not Yet Paid
OfferingCostsIncurredButNotYetPaid
135000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4724000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
1224000
CY2019Q2 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
2990000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
543000
us-gaap Profit Loss
ProfitLoss
-18004000
us-gaap Profit Loss
ProfitLoss
-8428000
us-gaap Share Based Compensation
ShareBasedCompensation
781000
us-gaap Share Based Compensation
ShareBasedCompensation
67000
us-gaap Depreciation
Depreciation
38000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1760000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1324000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3284000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
653000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1067000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
11000
lrmr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-89000
lrmr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-39000
lrmr Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-85000
lrmr Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-26000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-21000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-5000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21120000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8965000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
58000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
41934000
lrmr Payments Of Merger Transaction Costs
PaymentsOfMergerTransactionCosts
1233000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
40643000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33000
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
17995000
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
5990000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
75485000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
93480000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5990000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
113003000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3008000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1009000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4396000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
114012000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1388000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
4815000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
448000
lrmr Merger Transaction Costs Incurred But Not Yet Paid
MergerTransactionCostsIncurredButNotYetPaid
65000
us-gaap Noncash Or Part Noncash Acquisition Investments Acquired1
NoncashOrPartNoncashAcquisitionInvestmentsAcquired1
1000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expense, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Significant Suppliers </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company generally maintains cash balances in various operating accounts at financial institutions that management believes to be of high credit quality in amounts that may exceed federally insured limits. The Company has not experienced losses related to its cash and cash equivalents.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is highly dependent on third-party manufacturers to supply products for research and development activities in its programs. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of active pharmaceutical ingredients and formulated drugs.</p>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
328770
CY2020Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
37436000
CY2019Q4 lrmr Research And Development Tax Credit Sale Receivable
ResearchAndDevelopmentTaxCreditSaleReceivable
82000
CY2020Q2 lrmr Payroll Taxes Receivable
PayrollTaxesReceivable
55000
CY2019Q4 lrmr Payroll Taxes Receivable
PayrollTaxesReceivable
76000
CY2020Q2 lrmr Other Prepaid Expense And Other Current Assets
OtherPrepaidExpenseAndOtherCurrentAssets
446000
CY2019Q4 lrmr Other Prepaid Expense And Other Current Assets
OtherPrepaidExpenseAndOtherCurrentAssets
65000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
909000
lrmr Phase1 Clinical Trial Resume Period
Phase1ClinicalTrialResumePeriod
2020-07
lrmr Cash Cash Equivalents Restricted Cash And Marketable Debt Securities Acquired Merger
CashCashEquivalentsRestrictedCashAndMarketableDebtSecuritiesAcquiredMerger
42900000
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
lrmr Likelihood Percentage Minimum
LikelihoodPercentageMinimum
0.50
CY2020Q2 lrmr Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
628403
CY2020Q2 lrmr Warrant Excercise Price
WarrantExcercisePrice
0.01
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
727024
CY2020Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
40595000
CY2020Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Marketable Securities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
1014000
CY2020Q2 lrmr Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current And Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAndNoncurrentAssets
357000
CY2020Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
398000
CY2020Q2 lrmr Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash
1339000
CY2020Q2 lrmr Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Right Of Use Asset
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAsset
3806000
CY2020Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
2685000
CY2020Q2 lrmr Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation Noncurrent
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligationNoncurrent
5990000
CY2020Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
38834000
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
CY2020Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
36425000
CY2019Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2020Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2020Q2 lrmr Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
4926000
CY2019Q4 lrmr Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
3099000
CY2019Q4 lrmr Transaction Costs Capitalized
TransactionCostsCapitalized
419000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
453000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
234000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
179000
CY2020Q2 lrmr Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2290000
CY2019Q4 lrmr Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1295000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
516000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
119000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
526000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
337000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
464000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
508000
CY2020Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0047
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0200
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
202392
lrmr Share Based Compensation Arrangement By Share Based Payment Award Options Modification Of Stock Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsModificationOfStockOptions
128426
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
60479
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
720067
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
535922
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
720067
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.36
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice
74.80
lrmr Share Based Compensation Arrangement By Share Based Payment Award Options Modification Of Stock Options Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsModificationOfStockOptionsWeightedAverageExercisePrice
14.96
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.88
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
40.73
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
50.34
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
40.73
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M0D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y4M24D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
400
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
200
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
400
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
752000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
781000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
67000
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y29D
lrmr Milestone Expenses
MilestoneExpenses
0
CY2020Q2 lrmr Milestone Expenses
MilestoneExpenses
0
CY2019Q2 lrmr Milestone Expenses
MilestoneExpenses
0
lrmr Milestone Expenses
MilestoneExpenses
0
CY2020Q2 lrmr Milestone Liability
MilestoneLiability
0
CY2019Q2 lrmr Milestone Liability
MilestoneLiability
0
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.110
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.120
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
588000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1177000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1197000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1146000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1065000
CY2020Q2 lrmr Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
5397000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10570000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3711000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
6859000

Files In Submission

Name View Source Status
0001564590-20-040314-index-headers.html Edgar Link pending
0001564590-20-040314-index.html Edgar Link pending
0001564590-20-040314.txt Edgar Link pending
0001564590-20-040314-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g4cpqqtl1box000001.jpg Edgar Link pending
gmsy5aidt4wp000001.jpg Edgar Link pending
lrmr-10q_20200630.htm Edgar Link pending
lrmr-20200630.xml Edgar Link completed
lrmr-20200630.xsd Edgar Link pending
lrmr-20200630_cal.xml Edgar Link unprocessable
lrmr-20200630_def.xml Edgar Link unprocessable
lrmr-20200630_lab.xml Edgar Link unprocessable
lrmr-20200630_pre.xml Edgar Link unprocessable
lrmr-ex1010_302.htm Edgar Link pending
lrmr-ex106_306.htm Edgar Link pending
lrmr-ex107_305.htm Edgar Link pending
lrmr-ex108_304.htm Edgar Link pending
lrmr-ex109_303.htm Edgar Link pending
lrmr-ex311_55.htm Edgar Link pending
lrmr-ex312_53.htm Edgar Link pending
lrmr-ex321_54.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending